{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:23:41Z","timestamp":1772756621467,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd006570","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T00:00:00Z","timestamp":1223424000000}}],"reference-count":49,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006570.pub2","type":"journal-article","created":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T01:07:07Z","timestamp":1223514427000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses"],"prefix":"10.1002","author":[{"given":"Roger Carl","family":"Gibson","sequence":"first","affiliation":[{"name":"University of the West Indies; Department of Community Health & Psychiatry; Hospital Ring Road University Hospital of the West Indies Mona Kingston 7 Jamaica Kgn 7"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffery","family":"Walcott","sequence":"additional","affiliation":[{"name":"University Hospital of the West Indies; Department of Psychiatry; Hospital Ring Road University Hospital of the West Indies Kingston Jamaica KGN 7"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,8]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD006570.pub2-BIB0001|cit1","first-page":"409","article-title":"Clinical experimentation with the new drug LM-2717","volume":"6","author":"Arioni","year":"1971","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0002|cit2","first-page":"506","article-title":"Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia","volume":"149","author":"Barbee","year":"1992","journal-title":"American Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD006570.pub2-BIB0003|cit3","first-page":"1706","article-title":"Multifocal psychopharmaceutic testing (\"Multihospital trial\")","volume":"24","author":"Fischer Cornelssen","year":"1974","journal-title":"Arzneimittel Forschung"},{"issue":"10","key":"10.1002\/14651858.CD006570.pub2-BIB0004|cit4","first-page":"675","article-title":"A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients","volume":"28","author":"Hekimian","year":"1967","journal-title":"Diseases of the Nervous System"},{"issue":"6","key":"10.1002\/14651858.CD006570.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0010-440X(68)80059-8","article-title":"Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia","volume":"9","author":"Holden","year":"1968","journal-title":"Comprehensive Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006570.pub2-BIB0006|cit6","first-page":"43, 67","article-title":"Investigation of administering BZD medicament in outpatients with psychosis","volume":"12","author":"Hu","year":"2004","journal-title":"Heath Psychology Journal"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0007|cit7","first-page":"21","article-title":"Electroconvulsive therapy in lorazepam non-responsive catatonia","volume":"45","author":"Girish","year":"2003","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0008|cit8","unstructured":"Kunigiri G Gill NS B GN Naimmagadda J Electroconvulsive therapy in lorazepam non-responsive catatonia 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002 5458933"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/009127006600600203","article-title":"Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings","volume":"6","author":"Kurland","year":"1966","journal-title":"Journal of New Drugs"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1176\/ajp.117.4.362","article-title":"A comparative controlled study with chlordiazepoxide","volume":"117","author":"Smith","year":"1960","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0011|cit11","first-page":"153","article-title":"A clinical study of chlorpromazine and chlordiazepoxide","volume":"25","author":"Smith","year":"1961","journal-title":"Connecticut State Medical Journal"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0012|cit12","unstructured":"Ungvari GS Chow LY Chiu HFK Lau B Diiferent treatment response of distinct schizophrenia subtypes: the group of systematic catatonias 6th world Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France 1997"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Vasquez-Gomez F The use of midazolam for control of acutely agitated outpatients in psychiatry emergency 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany 2001","DOI":"10.3109\/15622970009150597"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0014|cit14","first-page":"527","article-title":"Clinical trial of RO 5-0690 and chlorpromazine on disturbed chronic schizophrenic patients","volume":"21","author":"Weckowicz","year":"1960","journal-title":"Diseases of the Nervous System"},{"issue":"7","key":"10.1002\/14651858.CD006570.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/archpsyc.1988.01800310072009","article-title":"Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients - preliminary results","volume":"45","author":"Wolkowitz","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006570.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1176\/ajp.143.1.85","article-title":"Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia","volume":"143","author":"WolkowitzOM","year":"1986","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006570.pub2-BIB0017|cit17","first-page":"291","article-title":"Benzodiazepine augmentation of neuroleptics in treatment resistant schizophrenia","volume":"28","author":"Wolkowitz","year":"1992","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0018|cit18","unstructured":"Wolkowitz OM Harris D Turetsky NG Reus VI Johnson R Gustafson M Espinoza S Petty F Cooper TB Sheline Y Hargreaves WA Alprazolam-neuroleptic treatment of schizophrenia 146th Annual Meeting of the American Psychiatric Association; 1993 May 22-27; San Francisco, California, USA 1993 119"},{"issue":"1","key":"10.1002\/14651858.CD006570.pub2-BIB0019|cit19","first-page":"126","article-title":"The use of midazolam in acutely agitated psychiatric patients","volume":"26","author":"Wyant","year":"1990","journal-title":"Psychopharmacology Bulletin"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006570.pub2-BIB0020|cit20","first-page":"S133","article-title":"A double-blind comparison of diazepam, chlordiazepoxide and chlorpromazine in psychotic patients","volume":"3","author":"Merlis","year":"1962","journal-title":"Journal of Neuropsychiatry"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0021|cit21","first-page":"91","article-title":"Outcome of lorazepam in catatonia oral vs parenteral administration","author":"Patra","year":"1998","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Schmider J Standhart H Deuschle M Drancoli J Heuser I A double blind comparison of lorazepam and oxazepam in psychogenic catatonia 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria 1997","DOI":"10.1016\/S0924-977X(97)88782-2"},{"issue":"3","key":"10.1002\/14651858.CD006570.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0006-3223(98)00312-6","article-title":"A double blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism","volume":"46","author":"Schmider","year":"1999","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0024|cit24","unstructured":"Pang AHT Ungvari G Ng FS Chiu H Treatment response of systematic catatonia (leonhard) to lorazepam 21st Collegium Internationale neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK 1998"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Ungvari G Pang A Ng F Chiu H Wong C Treatment response studies in systematic catatonia (leonhard). i. lorazepam challenge 8th Congress of the Association of European Psychiatrists; 1996 Jul 7-12; London, UK 1996","DOI":"10.1016\/0924-9338(96)89382-5"},{"issue":"4","key":"10.1002\/14651858.CD006570.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s002130050904","article-title":"Lorazepam for chronic catatonia: a randomized, double blind, placebo controlled cross over study","volume":"142","author":"Ungvari","year":"1999","journal-title":"Psychopharmacology Berlin"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0027|cit27","unstructured":"Wetzel H Klawe CJ Muller MJ Wiesner J Benkert O Lorazepam for stupor and mutism: a double-blind placebo-controlled cross-over study 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria 1997 79123210"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecing skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0029|cit29","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-IV TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006570.pub2-BIB0031|cit31","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0032|cit32","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa 2000"},{"issue":"6","key":"10.1002\/14651858.CD006570.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006570.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues.","volume":"31","author":"Elbourne","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0038|cit38","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] www.cochrane.org\/resources\/handbook\/hbook.htm"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0039|cit39","article-title":"Catatonia","volume-title":"Catatonia","author":"Kahlbaum","year":"1973"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0040|cit40","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1744-859X-5-14","article-title":"The catatonic dilemma expanded","volume":"5","author":"Penland","year":"2006","journal-title":"Annals of General Psychiatry"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jama.1977.03280070058025","article-title":"Sudden catatonic stupor with disastrous outcome","volume":"238","author":"Regestein","year":"1977","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0047|cit47","first-page":"357","article-title":"Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam","volume":"51","author":"Rosebush","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006570.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006570.pub2-BIB0049|cit49","volume-title":"ICD-10: international statistical classification of diseases and related health problems","author":"World Health Organization","year":"1992"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006570.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006570.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T10:05:43Z","timestamp":1684577143000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006570.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2008,10,8]]},"references-count":49,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006570.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD006570.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,8]]}}}